万古霉素治疗革兰阳性球菌感染重症肺炎的临床效果

Abstract
Figure/Table
References (15)
Related Citation (15)

Download: PDF (0 KB) HTML (32 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To study the clinical effect of Vancomycin in the treatment of severe pneumonia infected by Gram-positive cocci. Methods Eighty patients with severe pneumonia infected by Gram-positive cocci treated in our hospital from April 2016 to March 2019 were selected as the study subjects. The patients were divided into the control group and the observation group according to the random number table method, with 40 cases in each group. Patients in the control group were treated with Levofloxacin, and in the observation group, patients were treated with Vancomycin. The therapeutic effects, bacterial clearance rate, and adverse reactions in two groups after treatment were compared. Results The total effective rate of the observation group was 95.00%, which was higher than that of the control group accounting for 75.00%, and the difference was statistically significant (P＜0.05). The total bacterial clearance rate of the observation group was 95.00%, which was higher than that of the control group accounting for 75.00%, with statistical significance (P＜0.05). The total incidence of adverse reactions in the observation group was 5.00%, which was lower than that in the control group accounting for 22.5%, with statistical significance (P＜0.05). Conclusion Vancomycin is effective in the treatment of severe pneumonia caused by gram-positive cocci. It is safe and effective, which has less adverse reactions.

Key words： Vancomycin Gram-positive cocci Severe pneumonia Efficacy Mechanism Lung infection

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LI Jing
	DING Jin-feng
	XIAO Wen-xiang

Cite this article:

LI Jing,DING Jin-feng,XIAO Wen-xiang. Clinical effect of Vancomycin in the treatment of severe pneumonia infected by Gram-positive cocci[J]. 中国当代医药, 2020, 27(7): 185-187.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2020/V27/I7/185

[1]	王丹，刘春峰，张国安，等.重症肺炎合并先天性心脏病患儿万古霉素血药浓度分布特点分析及临床疗效观察[J].中国小儿急救医学，2018，25（10）：737-740.
[2]	杨斯博，司利钢，刘卓琼，等.利奈唑胺与万古霉素治疗儿童肺炎疗效对照分析[J].哈尔滨医科大学学报，2018，52（4）：383-386.
[3]	代伟，陈瑞祥，温瑾，等.重症肺炎患者应用万古霉素后血药谷浓度影响因素[J].热带医学杂志，2018，18（6）：795-798，834.
[4]	袁海燕，伏俊.万古霉素联合双黄连治疗耐甲氧西林金黄色葡萄球菌肺炎的临床效果分析[J].检验医学与临床，2018，15（16）：2490-2492.
[5]	高菲菲，陈超阳，周颖，等.重症肺炎患者使用万古霉素的药学监护[J].中国临床药理学杂志，2017，33（19）：1954-1955，1958.
[6]	刘春岭，李慧，张亚青，等.利奈唑胺与替考拉宁及万古霉素对脑梗死患者院内MRSA 肺炎疗效的对比探究[J].中华医院感染学杂志，2017，27（6）：1271-1274.
[7]	高永民.利奈唑胺万古霉素治疗耐甲氧西林金黄色葡萄球菌感染的疗效及安全性分析[J].河北医学，2017，23（9）：1448-1452.
[8]	陈春燕，朱素燕，周科挺，等.万古霉素谷浓度预测重症肺炎疗效及肾毒性的回顾性分析[J].中国现代应用药学，2016，33（9）：1188-1194.
[9]	孔程祥，王飞玲，李莉，等.儿童重症肺炎链球菌肺炎的感染状况、耐药性及血清型研究[J].中外医学研究，2019，17（20）：50-52.
[10]	陈静，钟皓成，姚君.不同氟喹诺酮类药物治疗老年社区获得性肺炎的临床观察及副作用探讨[J].中国现代医生，2016，54（34）：94-97.
[11]	何泽燕，赵秋良，费玲.替考拉宁对比万古霉素对耐甲氧西林金黄色葡萄球菌性呼吸机相关肺炎的疗效与安全性评价[J].贵州医药，2017，41（4）：367-369.
[12]	王月芳，钟伟，陈东琳.利奈唑胺、替考拉宁及万古霉素治疗院内MRSA 肺炎的临床观察[J].中国药房，2016，27（26）：3708-3710.
[13]	周庆涛，贺蓓，沈宁，等.肾清除率对老年重症肺炎患者体内万古霉素谷浓度的影响[J].中华结核和呼吸杂志，2016，39（2）：105-109.
[14]	王颖，刘英宇，郝颖艳.获得性MRSA 肺炎患者死亡率与血清万古霉素水平及MRSA 最低抑菌浓度相关性分析[J].中国急救医学，2016，36（6）：547-551.
[15]	程聪，苗新建，顾永丽.利奈唑胺与万古霉素治疗院内获得性肺炎疗效与安全性Meta 分析[J].中国药业，2016，25（1）：32-38.